

RESEARCH

Open Access

A framework for application of metabolic modeling in yeast to predict the effects of nsSNV in human orthologs

Hayley Dingerdissen¹, Daniel S Weaver², Peter D Karp², Yang Pan¹, Vahan Simonyan³ and Raja Mazumder^{1,4*}

Abstract

Background: We have previously suggested a method for proteome wide analysis of variation at functional residues wherein we identified the set of all human genes with nonsynonymous single nucleotide variation (nsSNV) in the active site residue of the corresponding proteins. 34 of these proteins were shown to have a 1:1:1 enzyme: pathway:reaction relationship, making these proteins ideal candidates for laboratory validation through creation and observation of specific yeast active site knock-outs and downstream targeted metabolomics experiments. Here we present the next step in the workflow toward using yeast metabolic modeling to predict human metabolic behavior resulting from nsSNV.

Results: For the previously identified candidate proteins, we used the reciprocal best BLAST hits method followed by manual alignment and pathway comparison to identify 6 human proteins with yeast orthologs which were suitable for flux balance analysis (FBA). 5 of these proteins are known to be associated with diseases, including ribose 5-phosphate isomerase deficiency, myopathy with lactic acidosis and sideroblastic anaemia, anemia due to disorders of glutathione metabolism, and two porphyrias, and we suspect the sixth enzyme to have disease associations which are not yet classified or understood based on the work described herein.

Conclusions: Preliminary findings using the Yeast 7.0 FBA model show lack of growth for only one enzyme, but augmentation of the Yeast 7.0 biomass function to better simulate knockout of certain genes suggested physiological relevance of variations in three additional proteins. Thus, we suggest the following four proteins for laboratory validation: delta-aminolevulinic acid dehydratase, ferrochelatase, ribose-5 phosphate isomerase and mitochondrial tyrosyl-tRNA synthetase. This study indicates that the predictive ability of this method will improve as more advanced, comprehensive models are developed. Moreover, these findings will be useful in the development of simple downstream biochemical or mass-spectrometric assays to corroborate these predictions and detect presence of certain known nsSNVs with deleterious outcomes. Results may also be useful in predicting as yet unknown outcomes of active site nsSNVs for enzymes that are not yet well classified or annotated.

Reviewers: This article was reviewed by Daniel Haft and Igor B. Rogozin.

Keywords: nsSNV, Ortholog, Sequence conservation, FBA, Yeast metabolic modeling

* Correspondence: mazumder@gwu.edu

¹Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Ross Hall, Room 540, 2300 Eye Street NW, Washington, DC 20037, USA

⁴McCormick Genomic and Proteomic Center, George Washington University, Washington, DC 20037, USA

Full list of author information is available at the end of the article

Background

An enzyme's active site specificity is an important determinant of functional catalysis. For this reason, if a nonsynonymous single nucleotide variation (nsSNV) occurs at the active site, thereby changing an active site amino acid residue, it is highly likely that enzyme activity will be lost or altered [1-7]. It follows that pathway activity should also be affected, with a potential end result of disease [8-10] or lethality.

In our previous paper [11] we used the SNVDis Tool [12], part of the High-performance Integrated Virtual Environment (HIVE) tools suite (accessed at hive.biochemistry.gwu.edu) [13] to identify the entire set of 559 human proteins with nonsynonymous variation at an active site residue resulting from a single nucleotide variation. Pathway, substrate and product annotation was manually retrieved from Kyoto Encyclopedia of Genes and Genomes (KEGG) [14] for all possible proteins in the dataset. To the best of our knowledge, a subset of 34 of the original proteins had a 1 enzyme:1 pathway:1 substrate/product set ratio, meaning these enzymes catalyze a single reaction for a single set of substrates and products and are currently annotated to participate in a single pathway. While there may be possible interaction between specified metabolites and alternative enzymes, the 1:1:1 relationship ensures no alternative metabolic interaction with the specified enzymes, thus making them suitable candidates for *in vivo* laboratory validation.

For this paper, we used the reciprocal best BLAST hits method [15] to query the set of 559 human active site nsSNV proteins against the yeast (*Saccharomyces cerevisiae*) proteome and, conversely, the top yeast protein hits back against the human proteome. We then checked for active site residue conservation and pathway/substrate/enzyme conservation between the 113 identified human-yeast orthologous pairs. We found 6 proteins which satisfied all criteria, 5 of which had human disease associations including anemias, porphyrias and others. The high incidence of dysfunction annotated among these active-site-nsSNV-containing proteins reinforces the notion that mutations in the active site disrupt normal enzyme and/or pathway activity. Although it may seem intuitive that the active site modifications are to blame for these disease associations, it is surprising to note that the disease-related annotations are not currently attributed to the active site variations for the 5 proteins in question, but are assigned to other sequence variations or causes.

Merely studying genomic variation may not be enough to determine the effects of active site variation, however, as one needs to examine the interactions and physiological outcome within the context of the cell, organ, or entire system [16]. Metabolic modeling is our attempt to test the impact of active site variation in a more

meaningful way as such methods get more sophisticated. To this end, we used the Yeast 7.0 flux balance analysis (FBA) model [17] to predict the effects of deleting these 6 proteins, constructed with the relevant nsSNV active site mutation, on the growth of yeast. Since several of these proteins are involved in production of important metabolites that are not contained within the Yeast 7.0 biomass function, we repeated the analysis using a revised biomass equation that incorporates the relevant metabolites. FBA is an established mathematical and computational approach for studying metabolic networks [18,19]. FBA modeling has a number of biotech applications as it allows programmatic prediction of a metabolic phenotype using *in silico* computations of reaction stoichiometry without using reaction kinetics [20-22]. FBA results have been shown to correlate well with experimental observations [23].

In the future, predictions given by this *in silico* cell model can be subjected to laboratory validation using yeast cultures with site-induced mutagenesis to alter the proper active site residue and observe the outcomes with respect to growth rate, substrate and product quantities, byproduct generation and general viability. We reason that the conservation of these protein sequences from yeast to humans, in conjunction with conserved active site residues and conserved pathway interplay, provides strong evidence that similar outcomes are likely to result from mutations in the human orthologs [24].

Our overarching goal is to better understand phenotypic effects of nsSNVs on the active site of enzymes. Although we use a small set of enzymes here to perform a preliminary proof of principle, this experiment lays the foundation for a method of cellular modeling that will move toward an “omics” approach with potential predictive ability. Similar large-scale studies already demonstrate the utility of this type of approach to predict metabolite concentrations related to environmental conditions [25], enzyme phosphorylation [26] and even whole gene deletion [27], but to the best of our knowledge there is no such effort to apply a metabolomics approach to the analysis of active-site- nsSNV-containing proteins to yield predictive and/or diagnostic information.

Results and discussion

The complete human and yeast proteomes, and all protein subsets, available from UniProtKB/Swiss-Prot, provide curated annotation information regarding both nsSNV and active sites [28]. The dbSNP database [29] provides additional information on variations and the Conserved Domain Database (CDD) [30] provides additional information on active sites. The SNVDis tool uses this information to return an output table with all human proteins containing nonsynonymous substitutions at the active site.

Note here that we do not discriminate between heterozygous and homozygous nsSNVs because pertinent

information is unavailable for the majority of human variation data. Previous findings imply that most nsSNVs in active sites are rare or heterozygous because they are expected to be selected against and, therefore, unlikely to be observed in a homozygous pair [31]. Studies of consanguineous families may prove a good source for detection of homozygous active site nsSNVs in the future, but there are currently few documented cases [32] of catalytic homozygote variants. This is problematic as currently available models assume the haploid condition of a yeast cell. Results of reducing the flux to zero in such a model cannot be easily generalized to a diploid, heterozygous state unless known loss of function via haploinsufficiency or dominant negative phenotypes is established. Although we cannot say with certainty that the variations presented in this paper confer this phenotype, there is literature evidencing the heterozygous loss of function associated with active site mutations in a number of mammalian genes including mouse DNA polymerase δ [33], human DNA polymerase γ [34] and mammalian 11 β -hydroxysteroid dehydrogenase type I [35]. Furthermore, the aforementioned murine study was extended from studies of homologous mutations in haploid yeast. Thus, while we cannot fully extend haploid modeling to proteins in diploid organisms, we suggest that yeast enzymes whose knockouts alter flux balance necessitate further attention be given to their orthologous human counterparts, for both homozygous and heterozygous variations. Specifically, we propose that haploid models could still provide quantitative value toward the development of predictive assays for highly conserved pathways in cases of true loss of function due to heterozygous mutation at human active sites.

A proteome-wide search in SNVDis returns 559 unique human proteins (Additional file 1: Table A1) with nsSNV at the active site. Subsequent pathway analysis using annotations from KEGG shows a subset of 34 proteins (updated from previous publication to include two additional proteins from the same set of 559 which were later found to meet the criteria) with nsSNV at the active site and a 1 enzyme:1 pathway:1 reaction relationship. Full methods and discussion for these and other preliminary results can be seen in the prior publication.

Reciprocal best BLAST hits method to identify human-yeast ortholog pairs

To identify proteins from yeast (*S. cerevisiae*) orthologous to the 559 active-site-nsSNV-containing human proteins, the reciprocal best BLAST hits method was used. The sequences for the 559 active-site-nsSNV-containing human proteins were extracted from UniProtKB/Swiss-Prot by UniProt Accession and used as the query in a BLAST [36] against the yeast proteome. Of the 559, 173 proteins have no hits against the yeast proteome with E-value less than

0.0001 and 146 proteins have significant hits but are deemed to be paralogous. Thus, 240 of the 559 human proteins are considered to have a one-way best hit. These 240 best-hit yeast proteins were then used as the query in a second BLAST against the entire human proteome. Of these 240, 127 have a unidirectional best-match such that the highest scoring yeast match from the human BLAST against the yeast proteome has an alternative highest-scoring human match when queried against the entire human proteome. This leaves 113 proteins with active site nsSNV to have a reciprocal best-match ortholog in yeast (Table 1, full reciprocal best BLAST hits data can be shown in Additional file 1: Table A2).

Identification of candidate enzymes for in vivo validation

To be considered ideal for laboratory validation, we want to first limit our consideration to the proteins in Table 2 which have a simple 1 enzyme:1 pathway:1 reaction relationship relationship. This 1:1:1 ratio drastically limits the possibility for an enzyme to affect or be affected by multiple metabolites during laboratory experiments. Of the 34 potential candidates, 11 had no best hit and 10 had a one-way best hit, leaving 11 proteins as potential candidates with reciprocal best-match orthologs.

We must also consider the case when the product of an enzymatic reaction can be synthesized by alternative means. For this paper, we decided to consider these cases due to literature supporting biochemical importance of dysfunction despite multiple pathways to product.

Additionally, we want to ensure the variable site of interest, the active site, is conserved across ortholog pairs. If functional residues are not conserved, we cannot say that experimental observations resulting from a variation in a yeast enzyme is at all indicative of outcomes of variation in the corresponding human enzyme. This was checked by manual examination of alignments (Figure 1). The minimum requirement for active site conservation is that the residue(s) annotated as the active site residue(s) are identical across species, although many of the human-yeast pairs have blocks of up to 10 amino acids conserved across species. 10 of the 11 ortholog pairs were conserved at the active site.

We want to further limit wet-lab candidate enzymes to those with no other orthologs or paralogs. Even though the proteins under consideration at this point are reciprocal best-matches, proteins with closely related homologs limit the confidence with which we can report results of laboratory validation experiments. For example, if a human protein has a best match with a yeast protein which has paralogs, we cannot be sure upon knockout of the enzyme that the paralogous proteins will not interfere in the metabolism we are trying to assay. Exclusion of proteins with orthologs and paralogs was performed by manually examining alignments. This exclusion now reduces our list

Table 1 Human proteins with active site nsSNV and their yeast ortholog match

Human protein	Yeast ortholog	Human protein	Yeast ortholog	Human protein	Yeast ortholog
Q9GZR2	Q08237	Q9P2J9	Q12511	Q15067	P13711
P49247	Q12189	Q9BZP6	Q06350	Q96S44	P53323
Q9UBZ4	P38207	O60825	P32604	O95154	P42884
Q14410	P32190	O15305	P07283	P78368	P23292
P51659	Q02207	Q9UNI6	Q02256	Q6PI48	P15179
P20618	P23724	Q96RR4	P43637	Q13164	Q00772
Q96T52	P46972	Q9NUW8	P38319	P06744	P12709
P08397	P28789	P00480	P05150	P11498	P32327
P04424	P04076	Q6IA69	P38795	P05186	P11491
P40818	P32571	Q04760	P50107	Q8TF76	P32789
Q8IWW8	P10127	P36873	P32598	P29120	P13134
P37268	P29704	Q9P2K8	P15442	Q8IWX5	P23501
Q96G46	Q06053	Q96GX9	P47095	Q96DP5	P32785
P48637	Q08220	Q13332	P25044	Q9Y3E5	P34222
P09467	P09201	P12955	P43590	P25789	P23638
Q9UGM6	P04803	P06132	P32347	P60484	P53916
P78549	P31378	O75191	P42826	P49917	Q08387
O96017	P39009	Q9H3S4	P35202	P32320	Q06549
Q7L3T8	P39965	P06737	P06738	Q9NSY1	P53974
Q9NYY3	P32562	Q13907	P15496	O60942	Q01159
O43426	P50942	P49841	P38615	Q9UGP5	P25615
O95363	P08425	P36871	P37012	Q9BUP3	P40008
P34949	P29952	Q9UBZ9	P12689	P54098	P15801
Q7L211	P42840	Q9HBY8	P12688	Q9UJM8	P00175
P07741	P49435	P07902	P08431	Q8WUX2	P32656
P13716	P05373	Q9Y2L1	Q08162	Q14249	P08466
P48449	P38604	Q96C11	Q04585	Q5VTY9	Q08929
P49336	P39073	O14818	P40303	Q86YJ6	P16120
Q8IZ73	Q12362	O00743	P20604	P12081	P07263
Q69YN2	P53255	Q5T2R2	P18900	Q9UQB9	P38991
Q99447	P33412	P04180	P40345	O14734	P41903
P30793	P51601	Q9Y3Q0	P47161	P14550	P14065
Q9BV23	P53750	O43175	P40054	P08243	P49090
P56937	Q12452	P22830	P16622	Q86V88	P40081
Q16769	P43599	O95336	P38858	Q8IXB1	P40564
Q15386	P53119	Q969P6	P04786	Q9Y3B8	P54964
Q9Y2H1	P53894	Q9Y2Z4	P48527	P00813	P53909
Q9UI42	P38836	Q9Y6R4	P53599		

This table lists the pool of 113 reciprocal best match human-yeast ortholog pairs, a subset from the original 559 proteins with active site nsSNV.

of potential candidates to 6. Table 3 lists the active site residue and surrounding conserved residues for these 6 proteins.

Finally, we want to make sure the ortholog pairs are involved in similar pathways. If a human protein has

diverged to act on different metabolites we again cannot use its yeast ortholog as a model to understand effects of variation in human proteins. Pathway information for the human proteins was previously retrieved and summarized in Table 2. Pathway information for the yeast proteins was

Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics

UniProtKB	Normal	Variation	Position	Substrate increased	Substrate ID	Product decreased	Product ID
A2RTX5	t	a	532	L-threonine	CID: 6288	L-threonyl-tRNA	SID: 5901
O43175	r	c	236	3-phospho-D-glycerate	CID: 439183	3-phosphonooxypyruvate	CID: 105
O75891	p	l	107	10-formyltetrahydrofolate	CID: 122347	Tetrahydrofolate	CID: 91443
O75908	h	q	434	cholesterol	CID: 5997	Cholesterol ester	SID: 5537
O75936	h	q	347	4-trimethylammoniobutanoate	CID: 134	Carnitine	CID: 85
O95336	r	c	185	6-phospho-D-glucono-1,5-lactone	CID: 439452	6-phospho-D-gluconate	CID: 91493
O95363	q	x	160	L-phenylalanine	CID: 6140	L-phenylalanyl-tRNA(Phe)	SID: 6321
O95479	r	c	728	Beta-D-glucose 6-phosphate	CID: 439427	6-phospho-D-gluconate	CID: 91493
O95861	a	v	221	PAPS	CID: 10214	Adenyl sulfate	CID: 10238
P04180	s	n	205	Phosphatidyl choline	SID: 3457	2-lysolecithin	SID: 6900
P09417	y	c	150	Tetrahydrobiopterin	CID: 44257	Dihydrobiopterin	CID: 133246
P13716	r	p	221	5-aminolevulinic acid	CID: 137	Porphobilinogen	CID: 1021
P22830	d	g	383	Ferrous ion protoporphyrin IX	CID: 27284 CID: 4971	Heme	CID: 444097
P23109	h	q	305	Adenylic acid	CID: 6083	Ammonia inosinic acid	CID: 222 CID: 8582
P23946	h	r	66	Angiotensin I	CID: 3081372	Angiotensin	CID: 172198
P25092	t	a	618	Guanosine 5'-triphosphate	CID: 6830	Cyclic gmp	CID: 24316
P42357	g	s	165	L-histidine	CID: 6274	Urocanic acid	CID: 736715
P43251	a	s	271	Biocytin	CID: 440721	Biotin L-lysine	CID: 171548 CID: 5962
P48637	r	c	125	Glycine gamma-glutamylcysteine	CID: 750 CID: 123938	Glutathione	CID: 124886
P49247	d	y	160	D-ribulose 5-phosphate	CID: 439184	Ribose 5-phosphate	CID: 439167
Q02127	t	i	284	L-dihydroorotic acid	CID: 439216	Orotic acid	CID: 967
Q02809	r	h	718	Protein lysine	SID: 5259	Procollagen 5-hydroxy-L-lysine	SID: 4433
Q16873	r	k	104	Leukotriene A4	CID: 5280383	Leukotriene C4	CID: 5280493
Q3SY69	y	x	127	10-formyltetrahydrofolate	CID: 122347	Tetrahydrofolate	CID: 91443
Q6PI48	r	x	266	L-aspartic acid	CID: 5960	L-aspartyl-tRNA(Asp)	SID: 5893
Q8IVS2	s	t	153	Malonyl-CoA	CID: 10663	Malonyl-[acyl-carrier-protein]	SID: 4431
Q8N5D6	y	x	121	Globoside	SID: 124490726	IV3GalNAca-Gb4Cer	SID: 124490727
Q8TDQ7	p	s	182	D-glucosamine phosphate	CID: 440997	Beta-D-fructose 6-phosphate	CID: 440641
Q96C23	r	x	82	Alpha-D-glucose	CID: 79025	Beta-D-glucose	CID: 64689
Q96GX9	g	r	47	S-methyl-5-thio-D-ribulose 1-phosphate	CID: 174549	5-(methylthio)-2,3-dioxopenyl phosphate	CID: 561
Q99487	h	r	314	Platelet-activating factor	SID: 7195	1-alkyl-sn-glycero-3-phosphocholine	SID: 6975

Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics (Continued)

Q9NVF9	n	s	94	Ethanolamine	CID: 700	Phosphoethanolamine	CID: 1015
Q9P2T1	g	d	242	Guanylic acid	CID: 6804	Inosinic acid	CID: 8582
Q9Y2Z4	g	s	243	L-tyrosine	CID: 6057	L-tyrosyl-tRNA(Tyr)	SID: 5781

This table provides the UniProtKB accession ID, normal and variable residues, position of the variation and substrate/product pairs with PubChem IDs for 34 proteins with annotated nsSNVs at the active site. These proteins were chosen for this study based on a one-protein, one-variation, one-substrate/product pair relationship to simplify preliminary modeling by ensuring no complex interactions for the given protein pathway.

NOTE: This table has been updated since the prior publication to include 2 additional proteins which were later identified to meet the criteria.

Query 15	SSVLAGGYNHPLLROWQS-ERQLTKNMLIFPLFISDNPDDFTIEIDSLPNINRIGVNRLKD	73
Sbjct 4	SVL GY HPLLR WQ+ L + LI+P+F++D PDD I SLP + R GV RL++	63
Query 74	YLKPLVAKGLRSVILFGVP-LIPGTKDPVGTAADDPAGPVIQGIKFIREYFPELYIICDV	132
Sbjct 64	L+PLV +GLR V++FGVP +P KD G+AAD P I+ I +R+ FP L + CDV	121
Query 133	CLCEYTSHGHCGVLYDDGTINRERSVSRLAAAVAVNYAKAGAHCVAPSMDIGRIRDIKRG	192
Sbjct 122	CLC YTSHHGCG+L ++G E S RLA VA+ YAKAG VAPSDM+DGR+ IK	181
Query 193	LINANLAHKTFVLSYAAKFSGNLYGPFRDAACSAFSN GDR+CYQLPPAGRGLARRALERD	252
Sbjct 182	L+ L ++ V+S+YAKF+ YGPFRDAA S++ GDR+CYQLPP RGLA RA++RD	241
Query 253	MAHGLGNRNSVMSYSAKFASCYGFPRDAAKSSFAF GDR+CYQLPPGARGLALRAVDRD	312
Sbjct 242	VREGADMMLVKPGMPYLDIVREVKDHPDLPLAVYHVSGEFAMLWHAQAGAFDLKAABL	301
Query 313	ESHQGFIRAGARLIITYLAPEFLDWLDEE 341	
Sbjct 302	EAMTAFFRAGADIIITYYTQQLLQWLKEE 330	

Figure 1 Manual verification of residue conservation at the active site in both human and yeast orthologs. This is the reciprocal best BLAST hits alignment using yeast protein P05373, Delta-aminolevulinic acid dehydratase for *S. cerevisiae*, as the query searching against the entire human proteome. The only human hit is P13716, also delta-aminolevulinic acid for *H. sapiens*. From genbank annotations, we know the active site should occur at position 221 in the human sequence, corresponding to position 232 in the yeast sequence. Here we see conservation not only among the active site residues, but also in the surrounding region, which can also be important in facilitating active site binding.

similarly retrieved from KEGG and recorded. Pathway conservation is indicated by similar pathway map with identical substrates and products. All 6 ortholog pairs were found to participate in the same pathways, acting on the same substrates and yielding the same products. Pathway information for these 6 proteins is included in Table 4. Further support for functional similarity can be seen in Figure 2, showing evidenced interactions (collected and curated following guidance by Lim et. al. [37] with other proteins and the distribution of functional human-yeast orthologs predicted by Isobase [38] among these subsets. A summary schema of the overall method used in identification of these 6 candidate proteins is presented in Figure 3.

Yeast 7.0 COBRA modeling

Five of the six identified candidate enzymes were input into the Yeast 7.0 model available at <http://pathway.yeast-genome.org/> [17]. Yeast methylthioribulose-1-phosphate dehydratase (MDE1), P47095, had no corresponding gene in the model and was therefore excluded from this analysis. When knockouts are generated in these genes, they all show normal growth rates except ribose-5-phosphate

isomerase (RPIA), Q12189, which showed no growth. However, Yeast 7.0 is not equipped to predict growth for all of these reactions because some important compounds and cofactors are not currently accounted for in the model. Findings are summarized in Table 5. (Full output available in Additional file 1: Table A3).

Modified yeast 7.0 modeling with updated biomass function

Under the consideration that a modeling tool with a more comprehensive biomass function could provide more information, we repeated modeling of the 5 relevant enzymes using a biomass function with added requirements for ferroheme b and charged tRNA(Tyr) in the mitochondrion. This model was able to implicate three additional proteins with function in essential reactions: delta-aminolevulinic acid dehydratase (ALADH), P05373; mitochondrial ferrochelatase, P16622; and mitochondrial tyrosine-tRNA ligase, P48527. This additional examination, in conjunction with sequence and pathway conservation, supports our argument for inclusion of the pertinent pathways in yeast cell models. A summary of the findings can be seen in Table 5. (see Additional file 1: Table A3 for full output).

The above Yeast 7.0 results, combined with literature support, sequence and pathway annotations, maintain our hypothesis that we should be able to use yeast orthologs with active site conservation to model the effect of a variation at the active site of its human ortholog in order to obtain a predictive overview of altered enzyme activity resulting from the variation. Furthermore, we see the potential for the utility of this method to improve as advanced modeling efforts continue to progress.

Biomedical relevance

We hypothesize that nonsynonymous variation in an enzyme's active site should have deleterious effects on

Table 3 Conserved residues between human and yeast orthologs at and around the active site

UniProtKB	Yeast AC	Human active site	Yeast active site	Conservation block
P13716	P05373	221 R	232 R	GDR + CYQLPP
P22830	P16622	383 D	361 D	+ADLV
P48637	Q08220	125 R	128 R	RSDY+
P49247	Q12189	160 D	107 D	DGADEV
Q96GX9	P47095	47 G	39 G	TGTGGGIS + K
Q9Y2Z4	P48527	243 G	261 G	+Q + GG + DQ

Table 4 Pathway comparison between human candidate proteins and yeast orthologs using KEGG pathway annotations

Human UniProt Ac	Gene name	Pathways	Yeast UniProt Ac	Yeast gene name	Pathway match?	Details
P13716	ALAD	Porphyrin and chlorophyll metabolism	P05373	HEM2	Yes	Same
		Biosynthesis of secondary metabolites			No	Pathway only annotated in yeast; same substrate/product
P22830	FECH	Porphyrin and chlorophyll metabolism	P16622	HEM15	Yes	Same
		Biosynthesis of secondary metabolites			No	Pathway only annotated in yeast; same substrate/product
P48637	GSS	Glutathione metabolism	Q08220	GSH2	Yes	Same
P49247	RPIA	Pentose phosphate pathway	Q12189	RKI1	Yes	Same
		Biosynthesis of secondary metabolites			No	Pathway only annotated in yeast; same substrate/product
Q96GX9	APIP	Cysteine and methionine metabolism	P47095	MDE1	Yes	Same
Q9Y2Z4	YARS2	Aminoacyl-tRNA biosynthesis	P48527	MSY1	Yes	Same

This table summarizes the pathway involvement of the six identified candidate proteins. For all 6 proteins, the primary pathway involvement is the same, down to the same products and substrates and the same place within a pathway. For three of the yeast proteins, however, the pathway annotation in KEGG listed an additional pathway not annotated for humans: "Biosynthesis of secondary metabolites." This is likely due to differential annotation between yeast and humans within KEGG. Because the substrates and products annotated for these pathways were identical to those of the primary pathways, these three proteins were not excluded and went onto analysis in the yeast FBA modeling.

the enzyme's activity and function. Although only one of the six human enzyme SNPs has a direct link to the Online Mendelian Inheritance in Man® database (OMIM®) [41] in dbSNP (rs28936396 in P48637, human glutathione synthetase linked to OMIM 266130 – Glutathione synthetase deficiency), all six have literature related to dysfunction and disease caused by variants found at other positions within the protein sequence. If our assumptions regarding active site variation are correct, then nsSNVs at the active site of enzymes involved in metabolic syndromes will likely alter protein function and contribute to similar syndromes. Furthermore, yeast orthologs for these enzymes with strong pathway and active site conservation may be used to verify the metabolic effects of such variation with respect to metabolite concentrations. Although the current Yeast 7.0 model supports this hypothesis for RPIA alone, we argue for inclusion of the pathways and metabolites associated with these proteins in future yeast models based on consideration of the augmented model findings, literature and conservation among orthologs. Thus, we present five potential disease-related proteins with active site nsSNVs (along with yeast orthologs) in need of laboratory experimentation to validate the veracity of disease related to the SNP.

Human P49247/Yeast Q12189


Ribose-5 phosphate isomerase (RPI) participates in the pentose phosphate pathway (PPP), an alternative pathway for glucose oxidation accounting for up to 20% of glucose

oxidation in normal tissue. [42] Synthesis of ribose 5-phosphate from ribulose 5-phosphate via RPI is required for nucleotide and nucleic acid synthesis, and participates in the downstream production of glycolytic intermediates [43]. With reduced RPI activity, ribose 5-phosphate becomes unavailable and the necessary glycolytic metabolites are not produced. Enzyme deficiency results in clinical symptoms of leukoencephalopathy and peripheral polyneuropathy. The RPIA gene has also been identified to be hypermethylated at CpG sites in breast cancer [44].

As of 2004, RPI was only the second known inborn error in the reversible portion of the PPP [45]; the PPP connects pentose phosphates to glycolytic intermediates. Furthermore, there are currently only 2 mutations listed in the Human Gene Mutation Database [46] (accessed 8/22/13) for the RPIA gene, neither of which is the aspartic acid to tyrosine variation at active site position 160 reported here (rs11549730). RPI has been observed to be variably conserved among species ranging from 52% similarity between human and *E. coli* to strong conservation noted between human and other mammals [47] and RKI1 disruption has been shown to be deleterious to yeast growth [48].

Human P13716/Yeast P05373

Delta-aminolevulinic acid dehydratase (ALADH), encoded by the ALAD gene in humans, catalyzes the first common step in heme and other tetrapyrrole biosynthesis [49] and has also been observed to interact with the proteasome



[50]. The wild-type enzyme exists as a high-activity homooctamer, but alternative lower-activity hexamer assemblies have been found [51]. In fact, naturally occurring ALAD porphyria-associated human variants have been shown to have an increased susceptibility to hexamer-stabilizing inhibitors. Lead-poisoning is also hallmark of reduced ALAD activity. 5-aminolevulinate accumulates as a result of the lowered activity and is responsible for the toxic

effects observed in both disease states. It has been suggested that small molecule stabilization of alternate oligomers (morpheeins) can be used as a therapy to target delta-aminolevulinic acid dehydratase [52], in addition to human immunodeficiency virus integrase, tumor necrosis factor α , mammalian ribonucleotide reductase and other disease-related proteins for which there is evidence of alternate, functionally differential oligomers [53].




Table 5 Summary of FBA results

Human	Yeast	Reaction tested	Yeast 7.0 results	
			Knock-out growth	Explanation
P13716	P05373	Porphobilinogen synthesis	No FBA growth	Ferroheme b + Yeast 7.0 biomass equation
P22830	P16622	Protoheme ferrochelatase	No FBA growth	Ferroheme b + Yeast 7.0 biomass equation
P48637	Q08220	Glutathione synthesis	WT growth ($\mu = 0.1405 \text{ hr}^{-1}$)	0 flux through reaction in WT (r_0485)
P49247	Q12189	Ribose-5-phosphate isomerization	No FBA growth	Phosphoribosyl-pyrophosphate block
Q96GX9	P47095	Methylthioribulose 1-phosphate dehydratase	Not determined	Gene not present in Yeast 7.0 model
Q9Y2Z4	P48527	Mitochondrial tyrosine-tRNA-ligase reaction	No FBA growth	Mitochondrial tRNA requirement + Yeast 7.0 biomass equation

P47095 impact could not be modeled as the Yeast 7.0 model contains no corresponding gene.

Mutants in the corresponding yeast HEM2 gene have been found to disrupt heme biosynthesis, requiring provision of heme for growth in culture [54]. Yeast and human ALADH differ with respect to Zn cofactor binding, thus care is required to ensure homology models account for this difference in stoichiometry [55]. However, comparison of primary sequences across a diverse array of species shows a strong degree of similarity in the region of the active site and a zinc-binding motif [56].

There are many studies discussing ALAD-porphyrin associated mutations [57,58] but responsibility for the disease state has not yet been assigned to the deletion at nucleotide position 843. Interestingly, this deletion in the active site codon also results in a frameshift, further complicating comprehension of potential disease mechanism(s).

Human P22830/Yeast P16622

Encoded by the FECH gene, ferrochelatase is the final enzyme in heme biosynthesis, catalyzing the formation of protoheme IX from protoporphyrin IX and ferrous iron [59]. Ferrochelatase is important to human health due to the critical and diverse functions of its product cofactor, heme. Defects in this enzyme have been related to erythropoietic protoporphyrin (EPP). EPP is a relatively benign disease with predominant manifestation of photosensitivity, although it has been reported with liver complications in 2-5% of patients [60]. Biological findings include elevated concentrations of protoporphyrin in erythrocytes, plasma and feces, and a large amount of protoporphyrin in the skin [61].

Comparisons between ferrochelatases of multiple species reveal the proteins belonging to human, mouse, chicken, frog and *Drosophila melanogaster* to be metalloenzymes with a [2Fe-2S] cofactor, thought to play a structural stabilizing role in humans [62]. The corresponding bacteria, yeast and plant proteins contain no iron-sulfur center, but the ferrochelatase from *S. cerevisiae* is similar in other respects to eukaryotic ferrochelatases. Yeast mutants with total or partial FECH activity deficiency and resultant protoporphyrin accumulation have been isolated [63].

Human Q9Y2Z4/Yeast P48527

Aminoacyl-tRNA synthetases (ARSs) catalyze the linkage of specific amino acids to their cognate tRNAs [64]. Mitochondrial tyrosyl-tRNA synthetase (TyrRS) is responsible for charging tyrosine to its tRNA. Although belonging to class I synthetases, tRNA recognition occurs in a way more common to class II ARSs [65]. Defects in TyrRS are associated with myopathy with lactic acidosis and sideroblastic anemia 2 (MLASA2). It has been proposed that diminished aminoacylation activity of the enzyme leads to decreased mitochondrial

protein synthesis and mitochondrial respiratory chain dysfunction [66]. TyrRS also has known involvement with cell-signaling [67] and angiogenesis [68]. Although there are multiple known disease-related TyrRS mutants, it is unclear for some mutants whether pathogenicity results from dysfunction in aminoacylation or cytokine activation.

Alignments with TyrRSs from several species reveals 34% identity with yeast and similarly low identity across the board, with greatest conservation confined to the N-terminus [69]. Gly-244 and Asp-246 are conserved among class I synthetase catalytically important residues, but a total of 8 residues are known to participate in hydrogen bonding [70].

Human Q96GX9/Yeast P47095

Methylthioribulose-1-phosphate dehydratase, encoded by the APIP (APAF1-interacting protein) gene, catalyzes the dehydratase step of the methionine salvage pathway, converting methylthioribulose-1-phosphate into 2,3 dioxomethylthiopentane-1-phosphate [71]. The methionine salvage pathway recycles sulfur metabolites by recovery of methionine from methylthioadenosine (MTA). This pathway plays a critical role in many biological functions including apoptosis, inflammation and cancer [72].

APIP is highly expressed in skeletal muscle and known for an anti-apoptotic role [73]. One common APIP SNP was observed to reduce enzyme activity, resulting in an increase in cell death in response to *Salmonella* [74].

Currently excluded from the Yeast 7.0 model, the MDH1 enzyme is of critical importance to the pathway. Loss of function leaves the cell with no isozymes for methionine salvage, as demonstrated in the YeastCyc pathway/genome database (PGDB) within BioCyc [75]. The enzyme and the entire methionine salvage pathway seem to be functionally conserved in yeast [76] and should therefore serve as an adequate model in yeast experimentation to validate predicted loss of function due to the contained nsSNV.

Conclusions

The method proposed by this series of studies can be generalized to identify all proteins affected by variation at functionally important residues, to determine the availability of orthologous yeast proteins to model the effects of such variation and, in the future, to predict and quantify cellular and potentially organismal responses to the variation. The specific analyses presented here for demonstration of the method further demonstrate that nonsynonymous single nucleotide variation at the active site should disrupt enzyme function and potentially induce disease in yeast. However, to fully and confidently extrapolate this finding to humans, disruption of enzyme function must be checked against the effects of zygosity.

This is currently a limitation imposed by existing data due to the lack of relevant frequency information for the majority of the variations studied. We have provided 6 sets of human/yeast enzyme ortholog pairs for which the human protein has been experimentally shown with nsSNV at the active site and the yeast enzyme has been verified to share important conserved properties. Each of these enzymes is known to have deleterious effects on human physiology when dysfunctional, but the loss of function has been directly related in OMIM to only one of the active site variants, glutathione synthetase. Thus, we present five viable candidates for variant-related disease discovery. Preliminary FBA modeling shows predictive support for one of these enzymes, ribose-5-phosphate isomerase. Experimental validation of these and similar findings will continue to increase the knowledge universe, in turn facilitating the development of more powerful, robust models. Advances in the technology employed by this method may enable the long-term creation of metabolite profiles associated with active site variation for corresponding human and yeast orthologs. Simple biochemical assays comparing human and yeast metabolite concentrations to the profiles could facilitate detection of active site non-synonymous variation. This may further lay the foundation for future diagnostic pipelines to predict unknown outcomes of active site nsSNVs in these and other enzymes.

Methods

Datasets and annotated information

Proteomes and all protein subsets were retrieved from UniProtKB/Swiss-Prot (UniProt release 2012_06 [28]. nsSNV data were extracted from UniProtKB/Swiss-Prot, dbSNP (build 135) [29], COSMIC (version 59) [77] and NCI 60 [78] (accessed June 28, 2012). The SNVDis tool (<https://hive.biochemistry.gwu.edu/snvdis.cgi?cmd=dmSnvdis>) [12] was used to retrieve the set of all proteins with nsSNVs at the active site (as annotated by UniProtKB/Swiss-Prot or CDD). Pathway information was retrieved from Kyoto Encyclopedia of Genes and Genomes (KEGG) [79] using the Protein Analysis Through Evolutionary Relationships (PANTHER) Classification System [80]. Substrate, product and disease information was gathered manually from KEGG and UniProtKB/Swiss-Prot. Official names and PubChem [81] Compound IDs (CIDs) for compounds with specific chemical structures, or Substance IDs (SIDs) for those without, were recorded for all substrates and products.

Analysis

Reciprocal best BLAST hits method

Stand-alone BLAST (version 2.2.27+) [82] was downloaded from the NCBI website. The yeast (*S. cerevisiae*) proteome was downloaded from Uniprot by using the term “Baker’s

yeast [559292]” for the field of Organism[OS], combined with the term “Complete proteome” in the Keyword field. The set of 559 previously selected human proteins was retrieved from Uniprot/Swiss-protKB in batch mode using the corresponding accession numbers.

The yeast proteome file was indexed as the database, and the human protein dataset was used as the query for the nucleotide-to-nucleotide Blastn algorithm with all default parameters and E-value higher than 10^{-5} . The customized script was developed to extract best hits from the Blastn result. All the yeast proteins that met the criteria were batch-retrieved from UniprotKB/Swiss-prot by accession numbers and prepared for the opposite direction BLAST. Reciprocal best BLAST hits method was then accomplished by using the selected yeast proteins as the query set to align against the indexed human proteome database downloaded from Uniprot following the similar method described above. A human-yeast ortholog table was generated via a customized script parsing the two-way BLAST results. Thus, only those proteins which are mutual best hits with p-value higher than 10^{-5} were marked as the ortholog.

Manual identification of orthologous pairs

Manual examination of BLAST alignment results was performed to verify residue conservation at and around the active site, as well as exclusion of proteins with additional homologs. Residue conservation was observed for all 6 candidate enzymes and reported as the longest continuous sequence conservation block containing the active site residue. Confirmation of active site annotation across species was achieved by consulting relevant databases. Manual confirmation of single-best-match orthologs was done by visual verification of BLAST results of corresponding human and yeast proteins performed separately with human and yeast as query species.

FBA procedures

COBRA simulations of the Yeast 7.0 genome-scale model were performed using Yeast 7.0.0 in the COBRA Toolbox 5.0.0 within MATLAB R2010a. In order to simulate the effects of knocking out genes YGL040C, YOR176W, and YPL097W, we added small (0.0005 mmol/gCDW/hr) requirements for ferroheme b and charged tRNA(Tyr) in the mitochondrion to the Yeast 7.0 biomass function, creating an augmented biomass function. Experimental evidence for these deletions drawn from the Saccharomyces Genome Database [83] suggests that YGL040C and YOR176W null mutants are inviable in large scale surveys, and that YPL097W mutants are deficient in respiration. Reference growth rates for wild-type cells lacking gene knockouts were obtained based on aerobic growth in glucose minimal media, using both the augmented and the original Yeast 7.0 biomass function. Additional file 1:

Table A3 contains fluxes obtained for simulations of wild-type cells using the augmented biomass function and are labeled as ‘augmented_flux’; while fluxes obtained for simulations of wild-type cells using the Yeast 7.0 biomass function are labeled as ‘7.00_flux’. Gene knockouts were simulated by limiting flux through the reaction carried out by the gene product in question to zero, equaling a total loss of function for that reaction. All COBRA simulations employed taxicab norm minimization of fluxes as described in the documentation for the optimizeCbModel function.

Reviewers' comments

We appreciate the reviewer's comments from Dr. Daniel Haft and from Dr. Igor B. Rogozin. We have revised the manuscript according to your comments and suggestions.

Reviewer 1: Dr. Daniel Haft

Previous work by this group identified 559 human enzymes in which missense mutations replace an enzyme's active site residue in rare alleles. Of these, 34 are assigned a single enzymatic activity rather than a panel of alternate substrates, with the reaction belonging to a single pathway in human as documented by KEGG. For this paper, the collection is winnowed further, to count only those for which bi-directional best BLAST matches between human and yeast identify putative ortholog pairs, uncomplicated by paralogs that could overlap in function. This stringent filter gets the list down to six enzymes, the topic of this paper. A tool for flux balance analysis (FBA) is available for yeast, but not for human. Thus, for these six enzymes, computation based on a yeast metabolic model leads to predictions that loss of the same function in human causes disease.

In one sense, there is no surprise here. Mutations away from the active site already were known to cause human disease for five of the six enzymes. Loss of the active site residue should be no less catastrophic to function than truncation or frameshift errors. It is possible that a heterozygous active site mutant could produce a currently unrecognized form of a disease now known only for homozygotes of an incompletely inactivated enzyme, but that is not the point of the paper. The yeast model is haploid. Presumably, the implications are for homozygotes of the mutant form in human.

Authors' response: *Perhaps it wasn't clear from our original discussion, but we agree that the haploid yeast model is only suited to truly “model” homozygous cases. However, we can envision potential scenarios in which a haploid model could still provide predictive quantitative value in assays in highly conserved pathways for loss of function due to heterozygous mutation at active sites in humans. We did revisit the text relevant to this issue and modified it to improve clarity.*

Furthermore, we are not claiming that homozygous alleles are altogether too rare, in fact the journal article we cite here (Ng PC1, Levy S, Huang J, Stockwell TB, Walenz BP, Li K, Axelrod N, Busam DA, Strausberg RL, Venter JC. *Genetic variation in an individual human exome. PLoS Genet.* 2008 Aug 15;4(8):e1000160) reports that just under 50% of all nonsynonymous SNPs in HuRef are homozygous. However, they go on report that only about 15% are likely to affect protein function in a deleterious way and in this case, heterozygous nsSNPs are two times more likely than homozygotes to be predicted to affect protein activity. Similarly, rare nsSNPs are twice as likely as common nsSNPs to affect protein function. Thus, at the active site and other functionally important residues, protein-affecting SNPs should be selected against and should be less likely to be observed in homozygote form.

At your suggestion, we conducted a new PubMed search and were able to find an article identifying a homozygous mutation in the catalytic domain of the MMP2 gene in two sisters with Winchester syndrome (Rouzier C1, Vanatka R, Bannwarth S, Philip N, Coussemant A, Paquis-Flucklinger V, Lambert JC. *A novel homozygous MMP2 mutation in a family with Winchester syndrome. Clin Genet.* 2006 Mar;69(3):271–6.) The long-term combination of (1) improved classification and annotation of variation data and (2) simple increase in available studies should allow us to find these cases and truly study the quantitative differences of heterozygous and homozygous states, ultimately helping to develop and refine possible detection assays.

The surprising finding, actually, seems to be that even under the stringent filtering used – conserved orthologs from yeast to human of enzymes in a conserved pathway – five of the six genes nominated for study are associated with described human genetic diseases, not simply non-viability. The alleles responsible for the genetic disorders seen in patients may encode enzymes that retain some residual function, probably more than an active site mutant retains, allowing for viability.

Rather than presenting a new method to find previously unrecognized human genetic disease, this paper forms a field test of the bioinformatics infrastructure one would need for such a pipeline in the future. If FBA is not yet available for human cells, the yeast model can stand in for a few validated human/yeast orthologs. When it turns out that zeroing activity of several genes causes no change, it suggests the FBA model needs repair. The authors describe making such repairs, on their way to completing their proof-of-principle for notion that a yeast metabolic model, and an infrastructure for data integration, could point the way to the prediction of diseases that could be caused by certain missense mutations.

Authors' response: *Thank you very much for your detailed comments and review which helped us to focus our editing efforts and improve our arguments.*

orthology. **Table A3.** Yeast 7.0 Outputs. Raw outputs from original and augmented Yeast 7.0 models.

Reviewer 2: Dr. Igor B. Rogozin

The authors analyzed nonsynonymous single nucleotide variations (nsSNVs) in active site residues in human-yeast protein alignments. This is a promising approach. I do not see major methodological problems. The only problem that I see is a discussion about "loss of function via haploinsufficiency or dominant negative phenotypes". I understand that this is a complex problem. For example, the vast majority of disease-associated mutations in the RPE65 gene (Poliakov E, Gubin AN, Stearn O, Li Y, Campos MM, Gentleman S, Rogozin IB, Redmond TM. Origin and evolution of retinoid isomerization machinery in vertebrate visual cycle: hint from jawless vertebrates. PLoS One. 2012;7: e49975) are recessive mutations. However a dominant mutation was recently found in this gene. This and many other examples (including those described in the paper) suggest that the problem of dominant mutations is extremely complex. I am not sure that the fraction of such mutations is high although I am not aware of such estimate in active site residues.

Authors' response: *Thank you for your positive comments regarding our approach and your general suggestions as well. We do realize the complexity of this issue and the necessity of exercising caution when applying models across organisms without knowing the full characterization of the deleterious outcome. As I mentioned in my response to Dr. Haft above, we have discussed the issue of zygosity, phenotype and loss-of-function both prior to the initial submission and since receipt of your responses. We do not want to ignore the modeling ramifications of differential ploidy, but we also don't want to exclude candidate proteins from downstream quantification steps as it may be possible that future in vivo assays (developed as a product of the broader study) can still have some impact on heterozygous disease states even if in silico models cannot properly simulate them. We have carefully reread and edited these sections in response to your comments and we feel that we have clarified our reasons for our treatments of these issues.*

Reviewer 3: Dr. I. King Jordan

This reviewer provided no comments for publication.

Additional file

Additional file 1: Table A1. SNVDis Results (duplicates removed). Results from initial SNVDis computation listing 934 SNPs found in annotated human active sites. **Table A2.** Recip. BLAST findings. Four column table: A – human uniprot accession; B – yeast best match to human protein from A in BLAST; C – human best match to yeast protein from B; D – yes if columns A and C match implying human and yeast proteins are reciprocal best matches and can therefore be considered for

Abbreviations

ALAD: Human gene encoding delta-aminolevulinic acid dehydratase; APIP: Human gene encoding methylthioribulose-1-phosphate dehydratase; ARS: Aminoacyl-tRNA synthetase; CID: PubChem Compound ID; CpG: Region of DNA where cytosine and guanine are separated by a single phosphate; EPP: Erythropoietic protoporphyrin; FBA: Flux balance analysis; FECH: Human gene encoding ferrochelatase; HIVe: High-performance integrated virtual environment; MDE1: Yeast gene encoding methylthioribulose-1-phosphate dehydratase; MLASA: Myopathy with lactic acidosis and sideroblastic anaemia; MTA: Methylthioadenosine; nsSNV: Nonsynonymous single nucleotide variation; PPP: Pentose phosphate pathway; RKI1: Yeast gene encoding ribose 5-phosphate isomerase; RPI: Ribose 5-phosphate isomerase; RPIA: Human gene encoding RPI; SID: PubChem substance ID; SNP: Single nucleotide polymorphism; TyrRS: Mitochondrial tyrosyl-tRNA synthetase.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RM, HD conceived and designed the analysis. HD carried out the manual analysis and identification of orthologs and drafted the manuscript. DW carried out all modeling experiments. YP performed reciprocal best BLAST hits method. DW and YP contributed text to relevant sections of manuscript. PDK, VS contributed analysis tools. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank Akos Vertes, Ph.D., Professor of Chemistry, Biochemistry and Molecular Biology at the George Washington University, for discussion and insight in the direction of this effort. Computations were performed at High-performance Integrated Virtual Environment (HIVE) located at The George Washington University and co-developed by Dr. Mazumder and Dr. Simonyan and at the Bioinformatics Research Group at SRI International, directed by Peter Karp. Support for this work came from The George Washington University funds to RM. This project is also supported in part by an appointment to the Research Participation program at the Center for Biologics Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration.

Author details

¹Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Ross Hall, Room 540, 2300 Eye Street NW, Washington, DC 20037, USA. ²Bioinformatics Research Group, Artificial Intelligence Center, SRI International Menlo Park, Menlo Park, CA 94025, USA.

³Center for Biologics Evaluation and Research, US Food and Drug Administration, 1451 Rockville Pike, Rockville, MD 20852, USA. ⁴McCormick Genomic and Proteomic Center, George Washington University, Washington, DC 20037, USA.

Received: 24 January 2014 Accepted: 19 May 2014

Published: 3 June 2014

References

1. Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, Leimkuhler S: The impact of single nucleotide polymorphisms on human aldehyde oxidase. *Drug Metab Dispos* 2012, 40:856–864.
2. Li CY, Yu Q, Ye ZQ, Sun Y, He Q, Li XM, Zhang W, Luo J, Gu X, Zheng X, Wei L: A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. *Cell Res* 2007, 17:357–362.
3. Aleem AM, Wells L, Jankun J, Walther M, Kuhn H, Reinartz J, Skrzypczak-Jankun E: Human platelet 12-lipoxygenase: naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior. *Int J Mol Med* 2009, 24:759–764.

4. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, Song R, Kang YM, Kang SW, Baek HJ, Kitaichi N, Meguro A, Mizuki N, Namba K, Ishida S, Kim J, Niemczyk E, Lee EY, Song YW, Ohno S, Lee EB: Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. *Ann Rheum Dis* 2013, **72**:1510–1516.
5. Renz KG, Cheetham BF, Walkden-Brown SW: Differentiation between pathogenic serotype 1 isolates of Marek's disease virus and the Rispens CVI988 vaccine in Australia using real-time PCR and high resolution melt curve analysis. *J Virol Methods* 2013, **187**:144–152.
6. Antonopoulos AS, Tousoulis D, Antoniades C, Miliou A, Hatzis G, Papageorgiou N, Demosthenous M, Tentolouris C, Stefanadis C: Genetic variability on adiponectin gene affects myocardial infarction risk: the role of endothelial dysfunction. *Int J Cardiol* 2012, **168**:326–330.
7. Nemoto H, Tate G, Kishimoto K, Saito M, Shirahata A, Umemoto T, Matsubara T, Goto T, Mizukami H, Kigawa G, Mitsuya T, Hibi K: Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum. *Cancer Genet* 2012, **205**:594–598.
8. Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ, Raghavan S, Ong E, Pastores GM, Kolodny EH: Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. *J Inherit Metab Dis* 2002, **25**:557–570.
9. Zankl A, Bonafe L, Calcaterra V, Di Rocca M, Superti-Furga A: Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2. *Clin Genet* 2005, **67**:261–266.
10. Ribaldo E, Doherty AJ, Dai Y, Stiff T, Oettinger MA, Jeggo PA, Kysela B: Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. *J Biol Chem* 2001, **276**:31124–31132.
11. Dingerdissen H, Motwani M, Karagiannis K, Simonyan V, Mazumder R: Proteome-wide analysis of nonsynonymous single-nucleotide variations in active sites of human proteins. *FEBS J* 2013, **280**:1542–1562.
12. Karagiannis K, Simonyan V, Mazumder R: SNVDs: a proteome-wide analysis service for evaluating nsSNVs in protein functional sites and pathways. *Genomics Proteomics Bioinformatics* 2013, **11**:122–126.
13. Wu TJ, Shamsaddini A, Pan Y, Smith K, Crichton DJ, Simonyan V, Mazumder R: A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE). *Database (Oxford)* 2014, **2014**:bau022.
14. Aoki KF, Kanehisa M: Using the KEGG database resource. *Current protocols in bioinformatics/editorial board, Andreas D Baxevanis [et al] 2005, Chapter 1:Unit 1 12.*
15. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, Koonin EV, Krylov DM, Mazumder R, Mekhedov SL, Nikolskaya AN, Rao BS, Smirnov S, Sverdlov AV, Vasudevan S, Wolf YI, Yin JJ, Natale DA: The COG database: an updated version includes eukaryotes. *BMC Bioinforma* 2003, **4**:41.
16. Noble D: Modeling the heart—from genes to cells to the whole organ. *Science* 2002, **295**:1678–1682.
17. Heavner BD, Smallbone K, Barker B, Mendes P, Walker LP: Yeast 5 – an expanded reconstruction of the *Saccharomyces cerevisiae* metabolic network. *BMC Syst Biol* 2012, **6**:55.
18. Orth JD, Thiele I, Palsson BO: What is flux balance analysis? *Nat Biotech* 2010, **28**:245–248.
19. Lakshmanan M, Koh G, Chung BK, Lee DY: Software applications for flux balance analysis. *Brief Bioinform* 2012, **15**:108–122.
20. Toya Y, Shimizu H: Flux analysis and metabolomics for systematic metabolic engineering of microorganisms. *Biotechnol Adv* 2013, **31**:818–826.
21. Khandelwal RA, Olivier BG, Roling WF, Teusink B, Bruggeman FJ: Community flux balance analysis for microbial consortia at balanced growth. *PLoS One* 2013, **8**:e64567.
22. Beg QK, Zampieri M, Klitgord N, Collins SB, Altafini C, Serres MH, Segre D: Detection of transcriptional triggers in the dynamics of microbial growth: application to the respiratory versatile bacterium *Shewanella oneidensis*. *Nucleic Acids Res* 2012, **40**:7132–7149.
23. Varma A, Boesch BW, Palsson BO: Stoichiometric interpretation of *Escherichia coli* glucose catabolism under various oxygenation rates. *Appl Environ Microbiol* 1993, **59**:2465–2473.
24. Lorenz A, Osman F, Sun W, Nandi S, Steinacher R, Whitby MC: The fission yeast FANCM ortholog directs non-crossover recombination during meiosis. *Science* 2012, **336**:1585–1588.
25. Ewald JC, Matt T, Zamboni N: The integrated response of primary metabolites to gene deletions and the environment. *Mol BioSyst* 2013, **9**:440–446.
26. Oliveira AP, Ludwig C, Picotti P, Kogadeeva M, Aebersold R, Sauer U: Regulation of yeast central metabolism by enzyme phosphorylation. *Mol Syst Biol* 2012, **8**:623.
27. Cooper SJ, Finney GL, Brown SL, Nelson SK, Hesselberth J, MacCoss MJ, Fields S: High-throughput profiling of amino acids in strains of the *Saccharomyces cerevisiae* deletion collection. *Genome Res* 2010, **20**:1288–1296.
28. Consortium U: Reorganizing the protein space at the universal protein resource (UniProt). *Nucleic Acids Res* 2012, **40**:D71–D75.
29. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielki EM, Sirotkin K: dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001, **29**:308–311.
30. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, Fong JH, Geer LY, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI, Jackson JD, Ke Z, Lanczycki CJ, Lu F, Marchler GH, Mullikindov M, Omelchenko MV, Robertson CL, Song JS, Thanki N, Yamashita RA, Zhang D, Zhang N, Zheng C, Bryant SH: CDD: a conserved domain database for the functional annotation of proteins. *Nucleic Acids Res* 2011, **39**:D225–D229.
31. Ng PC, Levy S, Huang J, Stockwell TB, Walenz BP, Li K, Axelrod N, Busam DA, Strausberg RL, Venter JC: Genetic variation in an individual human exome. *PLoS Genet* 2008, **4**:e1000160.
32. Rouzier C, Vanatka R, Bannwarth S, Philip N, Coussemant A, Paquis-Flucklinger V, Lambert JC: A novel homozygous MMP2 mutation in a family with Winchester syndrome. *Clin Genet* 2006, **69**:271–276.
33. Venkatesan RN, Treuting PM, Fuller ED, Goldsby RE, Norwood TH, Gooley TA, Ladiges WC, Preston BD, Loeb LA: Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis. *Mol Cell Biol* 2007, **27**:7669–7682.
34. Ponamarev MV, Longley MJ, Nguyen D, Kunkel TA, Copeland WC: Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis. *J Biol Chem* 2002, **277**:15225–15228.
35. Lawson AJ, Walker EA, Lavery GG, Bujalska IJ, Hughes B, Arlt W, Stewart PM, Ride JP: Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1. *Proc Natl Acad Sci U S A* 2011, **108**:4111–4116.
36. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. *J Mol Biol* 1990, **215**:403–410.
37. Lim YH, Charette JM, Baserga SJ: Assembling a protein-protein interaction map of the SSU processome from existing datasets. *PLoS One* 2011, **6**:e17701.
38. Singh R, Xu J, Berger B: Global alignment of multiple protein interaction networks with application to functional orthology detection. *Proc Natl Acad Sci U S A* 2008, **105**:12763–12768.
39. Orchard S, Ammari M, Aranda B, Breuza L, Brigandt L, Broackes-Carter F, Campbell NH, Chavali G, Chen C, del Toro N, Duesbury M, Dumousseau M, Galeota E, Hinz U, Iannuccelli M, Jagannathan S, Jimenez R, Khadake J, Lagreid A, Licata L, Lovering RC, Melidal B, Melidoni AN, Milagros M, Peluso D, Perfetto L, Porras P, Raghunath A, Ricard-Blum S, Roechert B, et al: The MintAct project-IntAct as a common curation platform for 11 molecular interaction databases. *Nucleic Acids Res* 2014, **42**:D358–D363.
40. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O'Donnell L, Reguly T, Breitkreutz A, Sellam A, Chen D, Chang C, Rust J, Livstone M, Oughtred R, Dolinski K, Tyers M: The BioGRID interaction database: 2013 update. *Nucleic Acids Res* 2013, **41**:D816–D823.
41. Online Mendelian Inheritance in Man, OMIM®. [http://omim.org/]
42. Wamelink MM, Struys EA, Jakobs C: The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. *J Inher Metab Dis* 2008, **31**:703–717.
43. Berg JM, Tymoczko JL, Stryer L: The Calvin Cycle and the Pentose Phosphate Pathway. In *Biochemistry*. 6th edition. New York, NY: W.H. Freeman and Company; 2007:565–591.
44. Kim JH, Kang HS, Kim TW, Kim SJ: Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer. *Int J Oncol* 2011, **39**:955–963.

45. Huck JH, Verhoeven NM, Struys EA, Salomons GS, Jakobs C, van der Knaap MS: Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy. *Am J Hum Genet* 2004, **74**:745–751.
46. Stenson PD, Ball EV, Mort M, Phillips AD, Shaw K, Cooper DN: The human gene mutation database (HGMD) and its exploitation in the fields of personalized genomics and molecular evolution. *Curr Protoc Bioinformatics* 2012, Chapter 1:Unit1.13.
47. Apel TW, Scherer A, Adachi T, Auch D, Ayane M, Reth M: The ribose 5-phosphate isomerase-encoding gene is located immediately downstream from that encoding murine immunoglobulin kappa. *Gene* 1995, **156**:191–197.
48. Kondo H, Nakamura Y, Dong YX, Nikawa J, Sueda S: Pyridoxine biosynthesis in yeast: participation of ribose 5-phosphate ketol-isomerase. *Biochem J* 2004, **379**:65–70.
49. Lawrence SH, Ramirez UD, Selwood T, Stith L, Jaffe EK: Allosteric inhibition of human porphobilinogen synthase. *J Biol Chem* 2009, **284**:35807–35817.
50. Bardag-Gorce F, French SW: Delta-aminolevulinic dehydratase is a proteasome interacting protein. *Exp Mol Pathol* 2011, **91**:485–489.
51. Inoue R, Akagi R: Co-synthesis of human delta-aminolevulinate dehydratase (ALAD) mutants with the wild-type enzyme in cell-free system-critical importance of conformation on enzyme activity. *J Clin Biochem Nutr* 2008, **43**:143–153.
52. Lawrence SH, Selwood T, Jaffe EK: Diverse clinical compounds alter the quaternary structure and inhibit the activity of an essential enzyme. *ChemMedChem* 2011, **6**:1067–1073.
53. Jaffe EK: Morphemeins - a new pathway for allosteric drug discovery. *Open Conf Proc J* 2010, **1**:1–6.
54. Golub EG, Liu KP, Dayan J, Adlersberg M, Sprinson DB: Yeast mutants deficient in heme biosynthesis and a heme mutant additionally blocked in cyclization of 2,3-oxidosqualene. *J Biol Chem* 1977, **252**:2846–2854.
55. Jaffe EK, Martins J, Li J, Kervinen J, Dunbrack RL Jr: The molecular mechanism of lead inhibition of human porphobilinogen synthase. *J Biol Chem* 2001, **276**:1531–1537.
56. Erskine PT, Newbold R, Brindley AA, Wood SP, Shoolingin-Jordan PM, Warren MJ, Cooper JB: The x-ray structure of yeast 5-aminolevulinic acid dehydratase complexed with substrate and three inhibitors. *J Mol Biol* 2001, **312**:133–141.
57. Akagi R, Shimizu R, Furuyama K, Doss MO, Sassa S: Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria. *Hepatology* 2000, **31**:704–708.
58. Jaffe EK, Stith L: ALAD porphyria is a conformational disease. *Am J Hum Genet* 2007, **80**:329–337.
59. Medlock A, Swartz L, Dailey TA, Dailey HA, Lanzilotta WN: Substrate interactions with human ferrochelatase. *Proc Natl Acad Sci U S A* 2007, **104**:1789–1793.
60. Lamoril J, Boulechfar S, de Verneuil H, Grandchamp B, Nordmann Y, Deybach JC: Human erythropoietic protoporphyria: two point mutations in the ferrochelatase gene. *Biochem Biophys Res Commun* 1991, **181**:594–599.
61. Aurizi C, Schneider-Yin X, Sorge F, Macri A, Minder EI, Biolcati G: Heterogeneity of mutations in the ferrochelatase gene in Italian patients with erythropoietic protoporphyria. *Mol Genet Metab* 2007, **90**:402–407.
62. Schneider-Yin X, Gouya L, Dorsey M, Rufenacht U, Deybach JC, Ferreira GC: Mutations in the iron-sulfur cluster ligands of the human ferrochelatase lead to erythropoietic protoporphyria. *Blood* 2000, **96**:1545–1549.
63. Labbe-Bois R: The ferrochelatase from *Saccharomyces cerevisiae*. Sequence, disruption, and expression of its structural gene HEM15. *J Biol Chem* 1990, **265**:7278–7283.
64. Yao P, Fox PL: Aminoacyl-tRNA synthetases in medicine and disease. *EMBO Mol Med* 2013, **5**:332–343.
65. Bonnefond L, Frugier M, Giege R, Rudinger-Thirion J: Human mitochondrial TyrRS disobeys the tyrosine identity rules. *RNA* 2005, **11**:558–562.
66. Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, Lim SC, Thorburn D, Ryan MT, Giege R, Bahlo M, Christodoulou J: Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia–MLASA syndrome. *Am J Hum Genet* 2010, **87**:52–59.
67. Wakasugi K, Schimmel P: Two distinct cytokines released from a human aminoacyl-tRNA synthetase. *Science* 1999, **284**:147–151.
68. Wakasugi K, Slike BM, Hood J, Ewalt KL, Cheresh DA, Schimmel P: Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. *J Biol Chem* 2002, **277**:20124–20126.
69. Bonnefond L, Fender A, Rudinger-Thirion J, Giege R, Florentz C, Sissler M: Toward the full set of human mitochondrial aminoacyl-tRNA synthetases: characterization of AspRS and TyrRS. *Biochemistry* 2005, **44**:4805–4816.
70. Bonnefond L, Frugier M, Touze E, Lorber B, Florentz C, Giege R, Sauter C, Rudinger-Thirion J: Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features. *Structure* 2007, **15**:1505–1516.
71. Albers E: Metabolic characteristics and importance of the universal methionine salvage pathway recycling methionine from 5'-methylthioadenosine. *IUBMB Life* 2009, **61**:1132–1142.
72. Mary C, Duek P, Salleron L, Tienz P, Bumann D, Bairoch A, Lane L: Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway. *PLoS One* 2012, **7**:e52877.
73. Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, Jung YK: Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. *J Biol Chem* 2004, **279**:39942–39950.
74. Ko DC, Gamazon ER, Shukla KP, Pfuetzner RA, Whittington D, Holden TD, Brittnacher MJ, Fong C, Radey M, Ogohara C, Stark AL, Akey JM, Dolan ME, Wurfel MM, Miller SL: Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. *Proc Natl Acad Sci U S A* 2012, **109**:E2343–E2352.
75. Karp PD, Ouzounis CA, Moore-Kochlacs C, Goldovsky L, Kaipa P, Ahren D, Tsoka S, Darzentas N, Kunin V, Lopez-Bigas N: Expansion of the BioCyc collection of pathway/genome databases to 160 genomes. *Nucleic Acids Res* 2005, **33**:6083–6089.
76. Pirkov I, Norbeck J, Gustafsson L, Albers E: A complete inventory of all enzymes in the eukaryotic methionine salvage pathway. *FEBS J* 2008, **275**:4111–4120.
77. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA: COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. *Nucleic Acids Res* 2011, **39**:D945–D950.
78. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS: The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. *Cancer Res* 2013, **73**:4372–4382.
79. Tanabe M, Kanehisa M: Using the KEGG database resource. *Current protocols in bioinformatics/editorial board, Andreas D Baxevanis [et al]* 2012, Chapter 1:Unit1.12.
80. Mi H, Guo N, Kejariwal A, Thomas PD: PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. *Nucleic Acids Res* 2007, **35**:D247–D252.
81. Bolton E, Wang Y, Thiessen PA, Bryant SH: PubChem: Integrated Platform of Small Molecules and Biological Activities. Chapter 12. In *Annual Reports in Computational Chemistry*. Volume 4, American Chemical Society; Washington, DC, 2008 Apr. <http://oldwww.acscomp.org/Publications/ARCC/volume4/chapter12.html>.
82. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 1997, **25**:3389–3402.
83. Cherry JM, Hong EL, Amundsen C, Balakrishnan R, Binkley G, Chan ET, Christie KR, Costanzo MC, Dwight SS, Engel SR, Fisk DG, Hirschman JE, Hitz BC, Karra K, Krieger CJ, Miyasato SR, Nash RS, Park J, Skrzypek MS, Simison M, Weng S, Wong ED: Saccharomyces genome database: the genomics resource of budding yeast. *Nucleic Acids Res* 2012, **40**:D700–D705.

doi:10.1186/1745-6150-9-9

Cite this article as: Dingerdissen et al.: A framework for application of metabolic modeling in yeast to predict the effects of nsSNV in human orthologs. *Biology Direct* 2014 **9**:9.